An in-depth review discussing two posters presented at ESC 2019

Join Professor John Camm in the discussion of :

  1. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in non-valvular atrial fibrillation – a cohort study in the 3 Scandinavian countries. – Professor Søren Paaske Johnsen
  2. Modifications of renal function in atrial fibrillation patients treated with different oral anticoagulants: a multicentre cohort study. – Assistant Professor Daniele Pastori

 

Register your email and provide your feedback

To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey

Speakers

Søren Paaske Johnsen

Aalborg Universteithospital

Aalborg, Denmark

Daniele Pastori

Sapienza University of Rome

Rome, Italy

  • Target audience
    This educational activity is designed for hospitalists, haematologists, interventional cardiologists, internists/physicians, surgeons, and any other healthcare professional with an interest or role in the management of patients on anticoagulation with life-threatening bleeds.
  • Learning objectives
    After completing these poster presentations, participants should be able to: • Recall the differences in the rates of stroke/systemic embolism and bleeding between patients receiving NOACs and those receiving warfarin, as seen in this retrospective cohort study. • Recall the differences in the changes of renal function in patients with atrial fibrillation treated with VKAs versus NOACs, as demonstrated by this study.
  • Disclosures
    Professor John Camm
    • Advisor for: Boehringer Ingelheim, Daiichi Sankyo
    • Consultant (retained) for: Boehringer Ingelheim
    • Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer
    Professor Søren Paaske Johnsen
    • Received speaker honoraria from Bayer, Bristol-Myers Squibb and Pfizer
    • Participated in advisory board meeting for Bayer, Bristol-Myers Squibb and Pfizer
    • Received research grants from Bristol-Myers Squibb and Pfizer
    Assistant Professor Daniele Pastori
    • None

    Staff and reviewer disclosures

    PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
  • Funding
    This independent educational activity is supported by funding from Portola Pharmaceuticals Inc. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run independently of the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.